XML 38 R24.htm IDEA: XBRL DOCUMENT v3.24.1
SCENDIA PURCHASE AGREEMENT (Tables) - Scendia Biologics LLC [Member]
 12 Months Ended
Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]  
SCHEDULE OF PURCHASE CONSIDERATIONS

The total purchase consideration, subject to typical post-closing adjustments, as determined by the Company was as follows:

   

Consideration  Equity Shares   Dollar Value 
Fair value of Sanara common shares issued   291,686   $6,032,066 
Cash consideration        1,562,668 
Fair value of contingent earnout consideration        3,000,000 
Total purchase consideration       $10,594,734 
SCHEDULE OF PURCHASE CONSIDERATION ON FAIR VALUE OF ASSETS ACQUIRED

 

Description  Amount 
Cash  $201,406 
Net working capital (excluding cash)   1,294,499 
Fixed assets, net   42,300 
Noncontrolling interest in Sanara Biologics, LLC   2,638 
Customer relationships   7,155,000 
Deferred tax liabilities   (1,702,890)
Goodwill   3,601,781 
Net assets acquired  $10,594,734